Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study (original) (raw)
Cost Analysis Comparing an Anthracycline/Docetaxel Regimen to CMF in Patients with Early Stage Breast Cancer
Angela Ihbe-heffinger, Ulrike Nitz
Onkologie, 2009
View PDFchevron_right
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
Miguel Casado
Clinical and Translational Oncology, 2010
View PDFchevron_right
Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer
Shail Verma
Current oncology (Toronto, Ont.), 2010
View PDFchevron_right
Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK
Anita Burrell
PharmacoEconomics, 2001
View PDFchevron_right
Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa
Kim MacQuilkan
Value in Health Regional Issues
View PDFchevron_right
Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
Mitsuru Sasako
European Journal of Clinical Pharmacology, 1996
View PDFchevron_right
The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
nahid hatam
Journal of Research in Medical Sciences
View PDFchevron_right
A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer: Docetaxel versus Paclitaxel versus Vinorelbine
Robert Launois
Pharmacoeconomics, 1996
View PDFchevron_right
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
Andrea Manca, Alastair Gray
European Journal of Cancer, 2011
View PDFchevron_right
An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK
Ágnes Benedict
PharmacoEconomics, 2009
View PDFchevron_right
A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer
Robert Launois
PharmacoEconomics, 1996
View PDFchevron_right
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation
Thang Long Vu
Annals of Oncology, 2007
View PDFchevron_right
A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer
Ningfeng Li
Anti-Cancer Drugs, 2001
View PDFchevron_right
PCN12: Cost-Utility Analysis Comparing Paclitaxel to Docetaxel in the Treatment of Metastatic Breast Cancer
Marvin Shepherd
Value in Health, 2001
View PDFchevron_right
Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer
G. van der Wilt
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2005
View PDFchevron_right
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial
Vassilis Fragoulakis
Annals of Oncology, 2008
View PDFchevron_right
A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735
Shail Verma
Current oncology (Toronto, Ont.), 2011
View PDFchevron_right
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran
nahid hatam
Asian Pacific journal of cancer prevention : APJCP, 2015
View PDFchevron_right
Pharmacoeconomic considerations in the treatment of breast cancer
Vasiliki Tsiantou
ClinicoEconomics and Outcomes Research, 2010
View PDFchevron_right
The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
Gerardus Frederix
PharmacoEconomics, 2014
View PDFchevron_right
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006
Bertrand Favier
Breast Cancer Research and Treatment, 2011
View PDFchevron_right
Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
Beate Jahn
BMC cancer, 2017
View PDFchevron_right
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial
Robert Mansel
2007
View PDFchevron_right
The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma
Jeannine McCune
Cancer, 2005
View PDFchevron_right
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
Andrea Botticelli, Elisa Martelli, Carlo Lazzaro
ClinicoEconomics and Outcomes Research, 2013
View PDFchevron_right
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal
J. Chilcott
Health technology assessment (Winchester, England), 2009
View PDFchevron_right
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
maryam ghiasipour
Cancer, 2007
View PDFchevron_right
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy
Susan Brunskill
Health technology assessment (Winchester, England)
View PDFchevron_right
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
T. Szucs
Annals of Oncology, 2007
View PDFchevron_right